Lantheus Holdings, Inc.

DB:0L8 Stock Report

Market Cap: €5.3b

Lantheus Holdings Valuation

Is 0L8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0L8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0L8 (€75.52) is trading below our estimate of fair value (€321.74)

Significantly Below Fair Value: 0L8 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0L8?

Key metric: As 0L8 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0L8. This is calculated by dividing 0L8's market cap by their current earnings.
What is 0L8's PE Ratio?
PE Ratio12.5x
EarningsUS$427.61m
Market CapUS$5.62b

Price to Earnings Ratio vs Peers

How does 0L8's PE Ratio compare to its peers?

The above table shows the PE ratio for 0L8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.4x
PHH2 Paul Hartmann
12xn/a€710.3m
AFX Carl Zeiss Meditec
25.7x16.3%€5.2b
FME Fresenius Medical Care
18.6x19.3%€12.3b
EUZ Eckert & Ziegler
21.3x4.0%€802.1m
0L8 Lantheus Holdings
12.5x13.9%€5.6b

Price-To-Earnings vs Peers: 0L8 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (19.4x).

Price to Earnings Ratio vs Industry

How does 0L8's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0L8 12.5xIndustry Avg. 29.9xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0L8 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the European Medical Equipment industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 0L8's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0L8 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.5x
Fair PE Ratio30.7x

Price-To-Earnings vs Fair Ratio: 0L8 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the estimated Fair Price-To-Earnings Ratio (30.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0L8 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€75.52
€126.90
+68.0%
12.8%€157.20€104.17n/a11
Nov ’25€99.86
€130.91
+31.1%
9.9%€158.50€113.21n/a11
Oct ’25€97.72
€130.91
+34.0%
9.9%€158.50€113.21n/a11
Sep ’25€94.30
€131.13
+39.1%
7.8%€152.91€115.84n/a10
Aug ’25€97.14
€131.13
+35.0%
7.8%€152.91€115.84n/a10
Jul ’25€74.36
€98.58
+32.6%
8.3%€119.60€89.70n/a10
Jun ’25€73.64
€97.63
+32.6%
8.5%€119.13€89.35n/a10
May ’25€62.36
€91.60
+46.9%
12.8%€120.26€77.04n/a10
Apr ’25€55.30
€89.73
+62.3%
12.9%€118.28€75.78n/a10
Mar ’25€60.54
€89.73
+48.2%
12.9%€118.28€75.78n/a10
Feb ’25€48.34
€84.29
+74.4%
8.1%€91.51€73.21n/a9
Jan ’25€55.90
€83.39
+49.2%
8.5%€90.89€72.71n/a8
Dec ’24€65.10
€102.87
+58.0%
10.4%€118.48€91.14n/a8
Nov ’24€60.90
€113.17
+85.8%
8.9%€123.63€95.10€99.867
Oct ’24€65.70
€114.64
+74.5%
7.0%€123.75€104.71€97.727
Sep ’24€63.32
€111.38
+75.9%
6.0%€118.13€99.96€94.307
Aug ’24€78.52
€112.12
+42.8%
5.2%€117.95€102.52€97.147
Jul ’24€76.32
€112.12
+46.9%
5.2%€117.95€102.52€74.367
Jun ’24€81.10
€112.12
+38.2%
5.2%€117.95€102.52€73.647
May ’24€77.24
€101.93
+32.0%
8.0%€109.21€86.46€62.367
Apr ’24€74.00
€103.34
+39.7%
9.9%€113.77€89.12€55.307
Mar ’24€69.50
€100.95
+45.3%
10.8%€113.75€85.31€60.546
Feb ’24€52.50
€93.91
+78.9%
11.2%€112.32€79.56€48.346
Jan ’24€47.20
€93.91
+99.0%
11.2%€112.32€79.56€55.906
Dec ’23€59.00
€98.19
+66.4%
11.4%€115.90€82.09€65.106
Nov ’23€75.00
€106.67
+42.2%
3.3%€113.37€103.06€60.906

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sensus Healthcare

US$112.8m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$6.45

7D

4.0%

1Y

251.1%

Ship Healthcare Holdings

JP¥194.6b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.30

7D

-9.6%

1Y

-4.7%

CVS Health

US$68.3b

Provides health solutions in the United States.

CVS

US$52.20

7D

-2.4%

1Y

-16.6%